In ovarian cancer patients, BRCA1 methylation was not associated with long-term responses [22], whereas, in patient-derived xenografts, a homozygous BRCA1 methylation status led to PARP inhibitor sensitivity [23]. The gene discussed is BRCA1; the disease is ovarian cancer.